Key opportunities include scalable platforms for antibodies, vaccines, biosimilars, and cell and gene therapies; single-use consumables and filtration; digital process control; sustainable manufacturing; workforce training; and partnerships.
Continuous Bioprocessing Market
Dublin, Aug. 31, 2026 (GLOBE NEWSWIRE) — The “Continuous Bioprocessing Market Size, Industry Dynamics, Opportunity Analysis and Forecast 2026-2035” has been added to ResearchAndMarkets.com’s offering.
Continuous Bioprocessing Market Projected to Reach USD 2.33 Billion by 2035
The global continuous bioprocessing market is gaining momentum as biopharmaceutical manufacturers prioritize efficient, scalable and reliable production technologies for complex biologics. Valued at USD 319.77 million in 2025, the market is projected to reach USD 2.33 billion by 2035, expanding at a compound annual growth rate of 21.98% from 2026 to 2035.
Market growth is being supported by increasing demand for manufacturing systems that reduce downtime, improve equipment utilization and deliver consistent product quality. Continuous bioprocessing platforms are becoming particularly important in the production of monoclonal antibodies, vaccines, biosimilars, and cell and gene therapies, where high throughput and stringent quality control are essential.
Competitive Landscape and Market Developments
Thermo Fisher Scientific, Sartorius, Danaher, through its Cytiva and Pall businesses, and Merck KGaA, operating as MilliporeSigma in the United States and Canada, hold influential positions in the continuous bioprocessing market. These suppliers provide instruments, consumables and integrated platforms that support implementation and commercial-scale manufacturing.
Strategic partnerships and capacity investments are strengthening the market’s development. In December 2025, Transcenta Therapeutics entered a non-exclusive licensing agreement with EirGenix for its highly intensified continuous bioprocessing platform. In July 2025, Asahi Kasei Life Science announced plans to establish a new spinning plant in Japan for Planova virus removal filters. Operations are scheduled to begin in 2030, expanding the supply of filtration products used to support biologics safety and purity.
Continuous Bioprocessing Market Growth Drivers
Rising global demand for biologic medicines is encouraging pharmaceutical and biotechnology companies to adopt manufacturing models capable of supporting rapid scale-up without compromising quality. Continuous bioprocessing improves production stability and throughput while helping manufacturers respond more effectively to commercial supply requirements and public health priorities.
The increasing prevalence of cancer, autoimmune disorders and infectious diseases is also supporting demand for monoclonal antibodies and vaccines. At the same time, expanding biosimilar pipelines and advances in cell and gene therapy are creating additional requirements for flexible, precisely controlled biomanufacturing capacity.
Sustainability and Digital Integration Create Opportunities
Sustainability is becoming a strategic priority across biopharmaceutical manufacturing, with 62% of biopharma executives identifying it as their foremost concern. Continuous production can support sustainability goals through more efficient resource utilization, smaller manufacturing footprints and lower material requirements.
Digital integration represents another significant opportunity. Advanced monitoring, automation, data analytics and process control technologies are being incorporated into continuous bioprocessing workflows to improve visibility, strengthen quality assurance and optimize manufacturing performance. These capabilities are expected to accelerate adoption as companies modernize production facilities.
Workforce Skills Remain a Key Market Challenge
A shortage of professionals with specialized continuous manufacturing expertise remains a barrier to implementation. Continuous production lines require technical skills that differ from those commonly used in batch processing. The resulting capability gap can increase execution risk during technology transfer, process validation and commercial scale-up, making workforce development an important priority for market participants.
Continuous Bioprocessing Market Segmentation
Consumables and reagents account for a leading market position because continuous operations depend on filters, tubing, bags, reagents and other single-use components. These products help maintain sterile processing conditions, limit cross-contamination risks and support uninterrupted manufacturing.
Monoclonal antibodies lead the application segment, supported by strong therapeutic demand across oncology, autoimmune disease and infectious disease treatment. Pharmaceutical and biotechnology companies represent the largest end-use segment due to their need for scalable production, shorter processing times and consistent output.
By Product
- Instruments
- Consumables and reagents
By Application
- Monoclonal antibodies
- Vaccines
- Cell and gene therapy
- Research and development
- Other applications
By End Use
- Pharmaceutical and biotechnology companies
- Contract manufacturing organizations and contract research organizations
- Research and academic institutes
Regional Market Outlook
North America holds 39% of the global continuous bioprocessing market, supported by advanced biopharmaceutical infrastructure, strong investment activity and regulatory confidence. Sanofi plans to invest USD 20 billion in manufacturing and research and development across the United States through 2030. The U.S. Food and Drug Administration approved 48 novel drugs in 2024, further reinforcing demand for scalable and dependable biologics manufacturing technologies.
The market is also analyzed across Europe, Asia Pacific, the Middle East and Africa, and South America. Asia Pacific is expected to benefit from expanding biomanufacturing capacity, growing biotechnology investment and increasing demand for biologic therapies.
Leading Continuous Bioprocessing Companies
- FUJIFILM Holdings Corporation
- Shimadzu Corporation
- Bionet
- Danaher Corporation
- Eppendorf SE
- Merck KGaA
- Repligen Corporation
- Sartorius AG
- Thermo Fisher Scientific Inc.
- WuXi Biologics
With biologics pipelines expanding and manufacturers pursuing higher productivity, the continuous bioprocessing market is positioned for substantial long-term growth. Technology innovation, digitalization, sustainability initiatives and investment in specialized workforce capabilities will remain central to successful adoption through 2035.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 280 |
| Forecast Period | 2025 – 2035 |
| Estimated Market Value (USD) in 2025 | $319.77 Million |
| Forecasted Market Value (USD) by 2035 | $2330 Million |
| Compound Annual Growth Rate | 21.9% |
| Regions Covered | Global |
Key Topics Covered:
Chapter 1. Executive Summary: Global Continuous Bioprocessing Market
Chapter 2. Research Methodology & Research Framework
2.1. Research Objective
2.2. Product Overview
2.3. Market Segmentation
2.4. Qualitative Research
2.4.1. Primary & Secondary Sources
2.5. Quantitative Research
2.5.1. Primary & Secondary Sources
2.6. Breakdown of Primary Research Respondents, By Region
2.7. Assumption for Study
2.8. Market Size Estimation
2.9. Data Triangulation
Chapter 3. Global Continuous Bioprocessing Market Overview
3.1. Industry Value Chain Analysis
3.1.1. Service Provider
3.1.2. End Consumers
3.2. Industry Outlook
3.2.1. Global R&D Expenditure
3.2.2. Top Biotechnology Hubs in the World, 2025
3.3. PESTLE Analysis
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitutes
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Growth and Outlook
3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
3.5.2. Price Trend Analysis, By Product Type
3.6. Market Attractiveness Analysis
3.6.1. By Product Type
3.6.2. By Region
3.7. Actionable Insights (Analyst’s Recommendations)
Chapter 4. Competition Dashboard
4.1. Market Concentration Rate
4.2. Company Market Share Analysis (Value %), 2025
4.3. Competitor Mapping & Benchmarking
Chapter 5. Global Continuous Bioprocessing Market Analysis
5.1. Market Dynamics and Trends
5.1.1. Growth Drivers
5.1.2. Restraints
5.1.3. Opportunity
5.1.4. Key Trends
5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
5.2.1. By Product Type
5.2.1.1. Key Insights
5.2.1.1.1. Instruments
5.2.1.1.1.1. Bioreactors
5.2.1.1.1.2. Filtration Systems
5.2.1.1.1.3. Chromatography Systems
5.2.1.1.1.4. Process Analytical Technologies
5.2.1.1.1.5. Others
5.2.1.1.2. Consumables & Reagents
5.2.1.1.2.1. Media & Buffers
5.2.1.1.2.2. Filters & Membranes
5.2.1.1.2.3. Resin
5.2.1.1.2.4. Tubing & Bags
5.2.1.1.2.5. Others
5.2.2. By Application
5.2.2.1. Key Insights
5.2.2.1.1. Monoclonal antibodies
5.2.2.1.2. Vaccines
5.2.2.1.3. Cell and gene therapy
5.2.2.1.4. Research & Development
5.2.2.1.5. Other applications
5.2.3. By End Use
5.2.3.1. Key Insights
5.2.3.1.1. Pharmaceutical and biotechnology companies
5.2.3.1.2. CMOs and CROs
5.2.3.1.3. Research and academic institutes
5.2.4. By Region
5.2.4.1. Key Insights
5.2.4.1.1. North America
5.2.4.1.1.1. The U.S.
5.2.4.1.1.2. Canada
5.2.4.1.1.3. Mexico
5.2.4.1.2. Europe
5.2.4.1.2.1. Western Europe
5.2.4.1.2.1.1. The UK
5.2.4.1.2.1.2. Germany
5.2.4.1.2.1.3. France
5.2.4.1.2.1.4. Italy
5.2.4.1.2.1.5. Spain
5.2.4.1.2.1.6. Rest of Western Europe
5.2.4.1.2.2. Eastern Europe
5.2.4.1.2.2.1. Poland
5.2.4.1.2.2.2. Russia
5.2.4.1.2.2.3. Rest of Eastern Europe
5.2.4.1.3. Asia Pacific
5.2.4.1.3.1. China
5.2.4.1.3.2. India
5.2.4.1.3.3. Japan
5.2.4.1.3.4. South Korea
5.2.4.1.3.5. Australia & New Zealand
5.2.4.1.3.6. ASEAN
5.2.4.1.3.6.1.1. Indonesia
5.2.4.1.3.6.1.2. Malaysia
5.2.4.1.3.6.1.3. Thailand
5.2.4.1.3.6.1.4. Singapore
5.2.4.1.3.6.1.5. Rest of ASEAN
5.2.4.1.3.7. Rest of Asia Pacific
5.2.4.1.4. Middle East & Africa
5.2.4.1.4.1. UAE
5.2.4.1.4.2. Saudi Arabia
5.2.4.1.4.3. South Africa
5.2.4.1.4.4. Rest of MEA
5.2.4.1.5. South America
5.2.4.1.5.1. Argentina
5.2.4.1.5.2. Brazil
5.2.4.1.5.3. Rest of South America
Chapter 6. North America Continuous Bioprocessing Market Analysis
6.1. Market Dynamics and Trends
6.1.1. Growth Drivers
6.1.2. Restraints
6.1.3. Opportunity
6.1.4. Key Trends
6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
6.2.1. By Product Type
6.2.2. By Application
6.2.3. By End Use
6.2.4. By Country
Chapter 7. Europe Continuous Bioprocessing Market Analysis
7.1. Market Dynamics and Trends
7.1.1. Growth Drivers
7.1.2. Restraints
7.1.3. Opportunity
7.1.4. Key Trends
7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
7.2.1. By Product Type
7.2.2. By Application
7.2.3. By End Use
7.2.4. By Country
Chapter 8. Asia Pacific Continuous Bioprocessing Market Analysis
8.1. Market Dynamics and Trends
8.1.1. Growth Drivers
8.1.2. Restraints
8.1.3. Opportunity
8.1.4. Key Trends
8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
8.2.1. By Product Type
8.2.2. By Application
8.2.3. By End Use
8.2.4. By Country
Chapter 9. Middle East & Africa Continuous Bioprocessing Market Analysis
9.1. Market Dynamics and Trends
9.1.1. Growth Drivers
9.1.2. Restraints
9.1.3. Opportunity
9.1.4. Key Trends
9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
9.2.1. By Product Type
9.2.2. By Application
9.2.3. By End Use
9.2.4. By Country
Chapter 10. South America Continuous Bioprocessing Market Analysis
10.1. Market Dynamics and Trends
10.1.1. Growth Drivers
10.1.2. Restraints
10.1.3. Opportunity
10.1.4. Key Trends
10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
10.2.1. By Product Type
10.2.2. By Application
10.2.3. By End Use
10.2.4. By Country
Chapter 11. Company Profiles (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)
11.1. FUJIFILM HOLDINGS CORPORATION
11.2. Shimadzu Corporation
11.3. Bionet
11.4. Danaher Corporation
11.5. Eppendorf SE
11.6. Merck KGaA
11.7. Repligen Corporation
11.8. Sartorius AG
11.9. Thermo Fisher Scientific Inc.
11.10. WuXi Biologics
11.11. Other Prominent Players
Chapter 12. Annexure
12.1. List of Secondary Leather Types
12.2. Key Country Markets – Macro Economic Outlook/Indicators
A selection of companies mentioned in this report includes, but is not limited to:
- FUJIFILM HOLDINGS CORPORATION
- Shimadzu Corporation
- Bionet
- Danaher Corporation
- Eppendorf SE
- Merck KGaA
- Repligen Corporation
- Sartorius AG
- Thermo Fisher Scientific Inc.
- WuXi Biologics
For more information about this report visit https://www.researchandmarkets.com/r/kli69h
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
- Continuous Bioprocessing Market
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
